Druker BJ - Search Results

1

Perspectives on the development of a molecularly targeted agent.

Druker BJ. Druker BJ. Cancer Cell. 2002 Feb;1(1):31-6. doi: 10.1016/s1535-6108(02)00025-9. Cancer Cell. 2002. PMID: 12086885 Free article. Review.

2

Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.

Druker B. Druker B. Semin Hematol. 2001 Jul;38(3 Suppl 8):9-14. doi: 10.1016/s0037-1963(01)90112-x. Semin Hematol. 2001. PMID: 11526596 Review.

3

STI571: a paradigm of new agents for cancer therapeutics.

Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. Mauro MJ, et al. Among authors: druker bj. J Clin Oncol. 2002 Jan 1;20(1):325-34. doi: 10.1200/JCO.2002.20.1.325. J Clin Oncol. 2002. PMID: 11773186 Review.

4

Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.

Druker BJ. Druker BJ. J Hematother Stem Cell Res. 2001 Dec;10(6):721-4. doi: 10.1089/152581601317210818. J Hematother Stem Cell Res. 2001. PMID: 11798498 No abstract available.

5

Recent advancements in the treatment of chronic myelogenous leukemia.

O'Dwyer ME, Mauro MJ, Druker BJ. O'Dwyer ME, et al. Among authors: druker bj. Annu Rev Med. 2002;53:369-81. doi: 10.1146/annurev.med.53.082901.103853. Annu Rev Med. 2002. PMID: 11818480 Review.

6

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

Heinrich MC, Blanke CD, Druker BJ, Corless CL. Heinrich MC, et al. Among authors: druker bj. J Clin Oncol. 2002 Mar 15;20(6):1692-703. doi: 10.1200/JCO.2002.20.6.1692. J Clin Oncol. 2002. PMID: 11896121 Review.

7

STI571 (Gleevec) as a paradigm for cancer therapy.

Druker BJ. Druker BJ. Trends Mol Med. 2002;8(4 Suppl):S14-8. doi: 10.1016/s1471-4914(02)02305-5. Trends Mol Med. 2002. PMID: 11927282 Review.

8

Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.

O'Dwyer ME, La Rosée P, Nimmanapalli R, Bhalla KN, Druker BJ. O'Dwyer ME, et al. Among authors: druker bj. Semin Hematol. 2002 Apr;39(2 Suppl 1):18-21. doi: 10.1053/shem.2002.33612. Semin Hematol. 2002. PMID: 12012318 Review.

9

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

Corbin AS, Buchdunger E, Pascal F, Druker BJ. Corbin AS, et al. Among authors: druker bj. J Biol Chem. 2002 Aug 30;277(35):32214-9. doi: 10.1074/jbc.M111525200. Epub 2002 Jun 20. J Biol Chem. 2002. PMID: 12077114 Free article.

10

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME. Braziel RM, et al. Among authors: druker bj. Blood. 2002 Jul 15;100(2):435-41. doi: 10.1182/blood.v100.2.435. Blood. 2002. PMID: 12091333 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

440 results

Search Page

Filters